Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Icenticaftor in Hepatic Impairment
NCT04587622Phase 1Completed
- Sponsor
- Novartis
- Start
- Oct 2020
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Icenticaftor in chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) (4 arms), sponsored by Novartis. Primary endpoints: Maximum observed plasma concentration at 168 hours, Area under the plasma concentration-time curve to last measurable concentration at 168 hours and 5 more. Started Oct 2020; status: completed.
02
Drugs
Icenticaftor
03
Conditions
chronic obstructive pulmonary disease (COPD)cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT04587622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04587622.